Intestinal levodopa infusion: The Belgian experience

Neurological Sciences

Volumn 35, Issue 6, 2014, Pages 861-866

  Pickut, Barbara Anne ^a   Van Der Linden, Chris ^b   Dethy, Sophie ^c   Van De Maele, Hilde ^d   De Beyl, Diederik Zegers ^e  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Department of Neurology AZ Sint Lucas ^*  (Belgium)

^c Centre Hospitalier Universitaire de Tivoli   (Belgium)

^d ABBVIE INC   (United States)

^e ERASME HOSPITAL   (Belgium)

Author keywords

Duodopa; Intestinal; LCIG; Levodopa; Parkinson's disease; UPDRS

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ANTIPARKINSON AGENT; CARBIDOPA; CARBIDOPA, LEVODOPA DRUG COMBINATION; DRUG COMBINATION; GEL; LEVODOPA;

ABDOMINAL PAIN; AGED; ARTICLE; BELGIUM; CONFIDENCE INTERVAL; CONFUSION; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EQUIPMENT FAILURE; FEMALE; FEVER; FOLLOW UP; HUMAN; JEJUNAL TUBE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MOTOR DYSFUNCTION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARKINSON DISEASE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; RATING SCALE; TREATMENT OUTCOME; UNITED PARKINSON DISEASE RATING SCALE IV; VISUAL ANALOG SCALE; ADMINISTRATION AND DOSAGE; CLINICAL TRIAL; DRUG COMBINATION; GEL; INTESTINE; MIDDLE AGED;

AGED; ANTIPARKINSON AGENTS; BELGIUM; CARBIDOPA; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; INTESTINES; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 84903378996     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-013-1612-5     Document Type: Article

References (15)

1. Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123:2297-2305
2. Fahn S (2000) The spectrum of levodopa-induced dyskinesias. Ann Neurol 47:S2-S9
3. Edwards LL, Quingley EMM, Pfeiffer RF (1992) Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 42:726-732
4. Mouradian MM, Juncos JL, Fabrini G, Chase TN (1989) Motor fluctuations in Parkinson's disease. Ann Neurol 25:633-634
5. Volkmann J, Albanese A, Antonini A et al (2013) Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol. doi:10.1007/s00415-012-6798-6
6. Nyholm D, Nilsson Remahl AI, Dizdar N et al (2005) Duodenal levodopa infusion monotherapy versus oral polypharmacy in advanced Parkinson disease. Neurology 64:216-223
7. Nilsson D, Nyholm D, Aquilonius SM (2001) Duodenal levodopa infusion in Parkinson's disease - long term experience. Acta Neurol Scand 104(6):343-348 (Pubitemid 33107378)
8. Antonini A, Isaias IU, Canesi M et al (2007) Duodenal levodopa infusion for advanced Parkinson's disease:12-months treatment outcome. Mov Disord 22:1145-1149 (Pubitemid 47067225)
9. Devos D, for the French Duodopa study group (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 24:993-1000
10. Honig H, Antonini A, Martinez-Martin P et al (2009) Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468-1474
11. Pålhagen SE, Dizdar N, Hauge T et al (2012) Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 126:29-33
12. Kristiansen IS, Bingefors K, Nyholm D, Isacson D (2009) Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden. An exploratory study. Appl Health Econ Health Policy 7:167-180
13. Willis M, Persson U, Zoellner Y, Gradl B (2010) Reducing uncertainty in value-based pricing using evidence development agreements. The case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa) in Sweden. Appl Health Econ Health Policy 8:377-386
14. Lowin J, Bergman A, Chaudhuri KR et al (2011) A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK. Med Econ 14:584-593
15. Antonini A, Odin P, Opiano L et al (2013) Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm 120:1553-1558